Results 241 to 250 of about 738,525 (387)
Journal of Bone and Mineral Research, Volume 38, Issue 1, Page 26-34, January 2023., 2023 ABSTRACT The combination of denosumab and teriparatide is an effective treatment strategy in postmenopausal osteoporosis, though skeletal gains are promptly lost when these agents are discontinued. In the DATA‐HD study, we reported that a single dose of zoledronic acid (ZOL) maintains the increases in areal spine and hip bone mineral density (BMD ...
Sabashini K. Ramchand +6 more
wiley +1 more source
Lipopolysaccharide‐Induced Bone Loss in Rodent Models: A Systematic Review and Meta‐Analysis
Journal of Bone and Mineral Research, Volume 38, Issue 1, Page 198-213, January 2023., 2023 ABSTRACT Osteoporosis has traditionally been characterized by underlying endocrine mechanisms, though evidence indicates a role of inflammation in its pathophysiology. Lipopolysaccharide (LPS), a component of gram‐negative bacteria that reside in the intestines, can be released into circulation and stimulate the immune system, upregulating bone ...
Kirsten N. Bott +6 more
wiley +1 more source
HU308 Mitigates Osteoarthritis by Stimulating Sox9‐Related Networks of Carbohydrate Metabolism
Journal of Bone and Mineral Research, Volume 38, Issue 1, Page 154-170, January 2023., 2023 ABSTRACT Osteoarthritis (OA) is characterized by progressive, irreversible erosion of articular cartilage accompanied by severe pain and immobility. This study aimed to assess the effect and mechanism of action of HU308, a selective cannabinoid receptor type 2 (CB2) agonist, in preventing OA‐related joint damage. To test the assumption that HU308 could
Idan Carmon +10 more
wiley +1 more source